The United States Food and Drug Administration (USFDA) has issued Form 483 with one observation after an inspection at Glenmark Pharmaceuticals’ formulation manufacturing facility based out of Aurangabad, India between June 27, 2022 and July 1, 2022.
The company is committed to undertake all necessary steps required to address their observation at the earliest. The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
